Elacestrant — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

8 Recruiting

2 Completed trials

9 Sponsors

19 Countries

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II: 4 Phase I/II: 3

Indications tested

Hormone receptor positive HER2 negative breast cancer 5 Androgen receptor assay 1 Breast cancer metastatic 1 Breast cancer male 1 Breast cancer female 1 Breast cancer 1 Hormone receptor positive breast cancer 1

Sponsors using this IMP

Stemline Therapeutics Inc. 4 Carrick Therapeutics Limited 1 Centro Di Riferimento Oncologico Di Aviano 1 Ellipses Pharma Limited 1 European Organisation For Research And Treatment Of Cancer 1 Istituto Europeo Di Oncologia S.r.l. 1 Medica Scientia Innovation Research S.L. 1 Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group 1 WSG Westdeutsche Studiengruppe GmbH 1

All trials

11 total

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negativ… Pending

2025-523460-21-00 Phase II 1 country Centro Di Riferimento Oncologico Di Aviano
The combination of Elacestrant and exemestane for patients with pretreated metastatic breast cancer expressing hormone receptors and non-exp… Recruiting

2024-519792-25-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 Phase III 3 countries WSG Westdeutsche Studiengruppe GmbH
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 Phase III 7 countries Medica Scientia Innovation Research S.L.; Stemline Therapeutics Inc.
ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I… Recruiting

2023-505758-17-00 Phase II 2 countries Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And…
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Phase III 15 countries Stemline Therapeutics Inc.
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety,Tolerability, Pharmacoki… Recruiting

2023-507738-26-00 Phase I/II 1 country Ellipses Pharma Limited
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Phase III 11 countries European Organisation For Research And Treatment Of Cancer
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting

2024-512878-98-00 Phase I/II 6 countries Stemline Therapeutics Inc.
ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label … Ended

2023-503214-68-00 Phase II 2 countries Stemline Therapeutics Inc.
A study to test the effect of Samuraciclib in Combination with Elacestrant in Participants with Hormone Receptor-positive (HR+) and Human Ep… Ended

2023-503846-30-00 Phase I/II 2 countries Carrick Therapeutics Limited

Showing 1–11 of 11 trials

← All drugs A–Z